BioAge Labs, Inc.
BioAge Labs, Inc. (BIOA) Financial Performance & Income Statement Overview
Explore the financials of BioAge Labs, Inc. (BIOA), including yearly and quarterly data on income, cash flow, and balance sheets.
BioAge Labs, Inc. (BIOA) Income Statement & Financial Overview
Access detailed annual and quarterly income data for BioAge Labs, Inc. BIOA financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $1.45M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $11.11M | $19.23M | $20.02M | $10.47M |
| SG&A Expenses | $6.79M | $6.14M | $4.73M | $4.80M |
| Operating Expenses | $17.90M | $25.36M | $24.75M | $15.27M |
| Total Costs & Expenses | $0.00 | $25.36M | $24.75M | $15.27M |
| Interest Income | $0.00 | $4.09M | $2.04M | $2.20M |
| Interest Expense | -$255000.00 | $319000.00 | $388000.00 | $443000.00 |
| Depreciation & Amortization | $0.00 | $47000.00 | $38000.00 | $49000.00 |
| EBITDA | -$16.45M | -$20.76M | -$22.98M | -$13.09M |
| EBITDA Ratio | -$11.33 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$16.45M | -$25.36M | -$24.75M | -$15.27M |
| Operating Income Ratio | -$11.33 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $3.52M | $4.23M | $1.34M | $1.69M |
| Income Before Tax | -$12.93M | -$21.13M | -$23.41M | -$13.58M |
| Income Before Tax Ratio | -$8.91 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$12.93M | -$21.13M | -$23.41M | -$13.58M |
| Net Income Ratio | -$8.91 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.36 | -$1.97 | -$6.70 | -$1.80 |
| Diluted EPS | -$0.36 | -$1.97 | -$6.70 | -$1.80 |
| Weighted Avg Shares Outstanding | $35.85M | $35.85M | $3.49M | $7.55M |
| Weighted Avg Shares Outstanding (Diluted) | $35.85M | $35.85M | $3.49M | $7.55M |
The company's financials show resilient growth, with revenue advancing from $0.00 in Q2 2024 to $1.45M in Q1 2025. Gross profit remained healthy with margins at N/A in Q1 2025 compared to N/A in Q2 2024. Operating income hit -$16.45M last quarter, sustaining a consistent -1133% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$16.45M. Net income rose to -$12.93M, while earnings per share reached -$0.36. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan